Gábor Kovács

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink et al. · Blood · 2015 · 700 citations · Full text

Life Sciences, Immunology, Oncology +8

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 622 citations

Medicine, Immunology, Oncology +14

Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002

Jan Starý, Martin Zimmermann, Myriam Campbell et al. · Journal of Clinical Oncology · 2013 · 341 citations · Full text

Medicine, Oncology, Pediatrics +15

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

Gábor Kovács, Sandra Robrecht, Anna Maria Fink et al. · Journal of Clinical Oncology · 2016 · 174 citations

Medicine, Hematology, Oncology +16

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, Anna Maria Fink, Raymonde Busch et al. · Blood · 2014 · 117 citations

Medicine, Oncology, Pharmacotherapy +15